Acadia Pharmaceuticals | ACAD - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cara Therapeutics USD 5.94M 983K 2025-09
Corcept Therapeutics USD 214.5M 16.87M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Eisai JPY 215.74B 15.84B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Incyte USD 5.62B 4.5B 2026-03
J&J USD 17.83B 388M 2026-06
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Prothena USD 25.29M 1.94M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03